Ankylosing Spondylitis (AS)Phase 2SELECT-AXIS 1NCT03178487
A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis
A Phase 2 study testing Upadacitinib in people with Ankylosing Spondylitis (AS), run by AbbVie at 101 sites in 21 countries.
Trial summary
The purpose of this study is to evaluate the safety and efficacy of upadacitinib in participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance to or a contraindication for NSAIDs, and who are naïve to biologic… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ankylosing Spondylitis (AS)
- What is being tested?
- Upadacitinib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 187 participants
- Where
- 101 sitesin 21 countries
- Study dates
- 24 Oct 2017to 17 Feb 2022
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participant with a clinical diagnosis of ankylosing spondylitis (AS) and meeting the modified New York criteria for AS.
- Participant must have baseline disease activity as defined by having a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score >= 4 and a Patient's Assessment of Total Back Pain score >= 4 based on a 0 - 10 numeric rating scale (NRS) at the Screening and Baseline visits.
- Participant has had an inadequate response to at least two nonsteroidal anti-inflammatory drugs (NSAIDs) over an at least 4-week period in total at maximum recommended or tolerated doses, or participant has an intolerance to or contraindication for NSAIDs as defined by the Investigator.
- If entering the study on concomitant methotrexate (MTX), leflunomide, sulfasalazine (SSZ), and/or hydroxychloroquine, participant must be on a stable dose of MTX (<= 25 mg/week) and/or SSZ (<= 3 g/day) and/or hydroxychloroquine (<= 400 mg/day) or leflunomide (<= 20 mg/day) for at least 28 days prior to the Baseline visit. A combination of up to two background conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) is allowed except the combination of MTX and leflunomide.
- If entering the study on concomitant oral corticosteroids, participant must be on a stable dose of prednisone (<= 10 mg/day), or oral corticosteroid equivalents, for at least 14 days prior to the Baseline visit.
- If entering the study on concomitant NSAIDs, tramadol, combination of acetaminophen and codeine or hydrocodone, and/or non-opioid analgesics, participant must be on stable dose(s) for at least 14 days prior to the Baseline visit.
Who cannot join
- Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib).
- Prior exposure to any biologic therapy with a potential therapeutic impact on spondyloarthritis (SpA).
- Intra-articular joint injections, spinal/paraspinal injection(s), or parenteral administration of corticosteroids within 28 days prior to the Baseline visit. Inhaled or topical corticosteroids are allowed.
- Participant on any other DMARDs (other than those allowed), thalidomide or apremilast within 28 days or five half-lives (whichever is longer) of the drug prior to the Baseline visit.
- Participant on opioid analgesics (except for combination acetaminophen/codeine or acetaminophen/hydrocodone which are allowed) or use of inhaled marijuana within 14 days prior to the Baseline visit.
- Participant has a history of inflammatory arthritis of different etiology other than axial SpA (including but not limited to rheumatoid arthritis, psoriatic arthritis, mixed connective tissue disease, systemic lupus erythematosus, reactive arthritis, scleroderma, polymyositis, dermatomyositis, fibromyalgia), or any arthritis with onset prior to 17 years of age.
- Laboratory values meeting the following criteria within the Screening period prior to the first dose of study drug: serum aspartate transaminase > 2 × upper limit of normal (ULN); serum alanine transaminase > 2 × ULN; estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal Disease formula < 40 milliliter (mL)/minute/1.73m^2; hemoglobin < 10 gram/deciliter, total white blood cell count < 2,500/microliter (μL); absolute neutrophil count < 1,500/μL; absolute lymphocyte count < 800/μL; and platelet count < 100,000/μL.
Trial locations and contacts
101 sites in 21 countries.
101 sites in 21 countries
United States22 sites
Diagnostic Group Integrated He /ID# 165195
Beaumont, Texas, 77701
David S. Hallegua MD /ID# 165090
Beverly Hills, California, 90211
Bay Area Arthritis and Osteo /ID# 165023
Brandon, Florida, 33511
DJL Clinical Research, PLLC /ID# 165044
Charlotte, North Carolina, 28210-8508
Arth and Osteo Clin Brazo Valley /ID# 165194
College Station, Texas, 77845
Covina Arthritis Clinic /ID# 165061
Covina, California, 91722
Henry Ford Health System /ID# 165515
Detroit, Michigan, 48202
Altoona Ctr Clinical Res /ID# 164470
Duncansville, Pennsylvania, 16635
St. Joseph Health System /ID# 166166
Fullerton, California, 92835
Aa Mrc Llc /Id# 165100
Grand Blanc, Michigan, 48439
Comprehensive Arthritis Care, a division of Comprehensive Rheumatology Care PLLC /ID# 168107
Hendersonville, Tennessee, 37075-6213
Colorado Arthritis Associates /ID# 164444
Lakewood, Colorado, 80228
Global Research Foundation /ID# 165130
Los Angeles, California, 90041
St. Lukes Clinic /ID# 165827
Meridian, Idaho, 83642
LeJenue Research Associates /ID# 165202
Miami, Florida, 33126
HMD Research LLC /ID# 205172
Orlando, Florida, 32819
Arizona Arthritis & Rheumatolo /ID# 164446
Phoenix, Arizona, 85032-9306
AZ Arthritis and Rheumotology Research, PLLC /ID# 165705
Phoenix, Arizona, 85032-9306
St. Lawrence Health System /ID# 165025
Potsdam, New York, 13676
Rheumatology Center of San Diego /ID# 166167
San Diego, California, 92128-2549
Clinical Investigation Specialists - Skokie /ID# 164385
Skokie, Illinois, 60076
Clinical Research Ctr Reading /ID# 164876
Wyomissing, Pennsylvania, 19610
Japan17 sites
National Hospital Organization Asahikawa Medical Center /ID# 164566
Asahikawa-shi, Hokkaido, 070-8644
Juntendo University Hospital /ID# 164738
Bunkyo-ku, Tokyo, 113-8431
St.Luke's International Hospital /ID# 165219
Chuo-ku, Tokyo, 104-8560
Saitama Medical University Hospital /ID# 164577
Iruma-gun, Saitama, 350-0451
National Hospital Organization Osaka Minami Medical Center /ID# 164365
Kawachinagano-shi, Osaka, 586-8521
Kagawa University Hospital /ID# 167517
Kita-gun, Kagawa-ken, 761-0793
Hospital of the University of Occupational and Environmental Health /ID# 164380
Kitakyushu-shi, Fukuoka, 807-8556
Juntendo University Koshigaya Hospital /ID# 165809
Koshigaya-shi, Saitama, 343-0032
Gunma University Hospital /ID# 165683
Maebashi, Gunma, 371-8511
Shinshu University Hospital /ID# 165304
Matsumoto-shi, Nagano, 390-8621
Daido Hospital /ID# 163886
Nagoya, 457-8511
Kochi Medical School Hospital /ID# 164460
Nankoku-shi, Kochi, 783-8505
Japanese Red Cross Okayama Hospital /ID# 164376
Okayama, Okayama-ken, 7008607
Okayama Saiseikai Outpatient Center Hospital /ID# 165595
Okayama, 700-0013
Osaka City University Hospital /ID# 165253
Osaka, Osaka, 545-8586
Osaka University Hospital /ID# 166033
Suita-shi, Osaka, 565-0871
Tokushima University Hospital /ID# 165108
Tokushima, Tokushima, 770-8503
South Korea7 sites
Chonnam National University Hospital /ID# 164541
Gwangju, Jeonranamdo, 61469
Gachon University Gil Medical Center /ID# 165114
Incheon, Incheon Gwang Yeogsi, 21565
Chungnam National University Hospital /ID# 164561
Junggu, Daejeon Gwang Yeogsi, 35015
Hanyang University Seoul Hospi /ID# 165811
Seongdong-gu, Seoul Teugbyeolsi, 04763
Cath Univ Seoul St Mary's Hosp /ID# 164549
Seoul, Seoul Teugbyeolsi, 06591
Kyunghee University Hospital at Gangdong /ID# 164569
Seoul, 02447
Asan Medical Center /ID# 164557
Seoul, 05505
Portugal5 sites
Instituto Portugues De Reumatologia /ID# 168314
Lisbon, Lisbon District, 1050-034
Centro Hospitalar Lisboa Ocidental, EPE /ID# 168312
Lisbon, Lisbon District, 1349-019
Hospital CUF Descobertas /ID# 168311
Lisbon, 1998-018
Unidade Local De Saude Do Alto Minho /ID# 168310
Viana do Castelo, 4901-858
Centro Hospitalar de Vila Nova Gaia/Espinho, EPE /ID# 168313
Vila Nova de Gaia, Porto District, 4434-502
United Kingdom5 sites
Royal National Hosp for Rheuma /ID# 165147
Bath, BA1 1RL
Glasgow Royal Infirmary /ID# 165152
Glasgow, G4 0SF
Whipps Cross Univ Hospital /ID# 165150
London, London, City of, E11 1NR
Norfolk and Norwich Univ Hosp /ID# 165149
Norwich, Norfolk, NR4 7UY
Warrington and Halton Hospitals NHS Foundation Trust /ID# 166202
Warrington, Cheshire West And Chester, WA5 1QG
Canada4 sites
Rheumatology Research Assoc /ID# 165240
Edmonton, Alberta, T5M 0H4
University of Alberta - Division of Rheumatology /ID# 165239
Edmonton, Alberta, T6G 2B7
Credit Valley Rheumatology /ID# 200087
Mississauga, Ontario, L5M 2V8
Groupe de Recherche en Maladies Osseuses Inc /ID# 165238
Sainte-Foy, Quebec, G1V 3M7
Czechia4 sites
REVMACLINIC s.r.o. /ID# 167171
Brno, 611 41
ARTHROHELP, s.r.o. /ID# 167001
Pardubice, 530 02
Revmatologicky ustav Praha /ID# 167004
Prague, Praha 2, 128 00
Thomayerova nemocnice /ID# 167003
Prague, Praha 4, 140 00
Germany4 sites
Kerckhoff Klinik GmbH /ID# 165158
Bad Nauheim, 61231
Charite - Campus Benjamin Franklin Medizinische Klinik - Rheumatologie /ID# 165153
Berlin, 12203
Hamburger Rheuma Forschungszentrum II im MVZ Rheumatologie und Autoimmunmedizin /ID# 165146
Hamburg, 20095
Rheumazentrum Ruhrgebiet /ID# 165148
Herne, North Rhine-Westphalia, 44649
Hungary4 sites
Revita Reumatologiai Rendelo /ID# 164724
Budapest, 1027
University of Debrecen /ID# 165674
Debrecen, 4032
Vita Verum Medical Bt. /ID# 165066
Székesfehérvár, 8000
Vital Medical Center Orvosi-es Fogaszati Kozpont /ID# 164741
Veszprém, 8200
Italy4 sites
Ospedale Sant Orsola Malpighi /ID# 165692
Bologna, Emilia-Romagna, 40138
ASST G. Pini /ID# 165715
Milan, 20122
Policlinico Paolo Giaccone /Id# 165663
Palermo, Sicily, 90127
A.O. Universitaria Senese /ID# 165716
Siena, 53100
Belgium3 sites
ReumaClinic Genk /ID# 166018
Genk, 3600
UZ Gent /ID# 166017
Ghent, Oost-Vlaanderen, 9000
UZ Leuven /ID# 166019
Leuven, 3000
France3 sites
CHU Bordeaux-Hopital Pellegrin /ID# 166309
Bordeaux, 33076
CHRU Tours - Hopital Trousseau /ID# 165109
Chambray-lès-Tours, 37170
CHRU de Montpellier - Hôpital Lapeyronie /ID# 166308
Montpellier, 34090
Poland3 sites
Osteo-Medic S.C. /ID# 165646
Bialystok, Podlaskie Voivodeship, 15-351
ETYKA-Osrodek Badan Klinicznyc /ID# 165634
Olsztyn, Warmian-Masurian Voivodeship, 10-117
NZOZ Nasz Lekarz /ID# 166023
Torun, 87-100
Spain3 sites
Hospital Parc de Salut del Mar /ID# 165027
Barcelona, 08003
Corporac Sanitaria Parc Tauli /ID# 165029
Barcelona, 08006
Hospital Unversitario Marques de Valdecilla /ID# 165028
Santander, Cantabria, 39008
Australia2 sites
Emeritus Research /ID# 169240
Camberwell, Victoria, 3124
Princess Alexandra Hospital /ID# 169239
Woolloongabba, Queensland, 4102
Croatia2 sites
Clinical Hospital Dubrava /ID# 167049
Zagreb, 10000
Medical Center Kuna-Peric /ID# 164851
Zagreb, 10000
Finland2 sites
Helsinki Univ Central Hospital /ID# 165794
Helsinki, 00290
Kiljava Medical Research /ID# 165793
Hyvinkää, 05800
Netherlands2 sites
Universitair Medisch Centrum Groningen /ID# 165681
Groningen, 9713 GZ
Medisch Centrum Leeuwarden /ID# 166937
Leeuwarden, 8934 AD
New Zealand2 sites
Middlemore Hospital /ID# 169241
Auckland, 2025
Waikato Hospital /ID# 169242
Hamilton, Waikato Region, 3204
Sweden2 sites
Skanes Universitetssjukhus /ID# 165712
Malmö, Skåne County, 214 28
Reumatologkliniken /ID# 165713
Västerås, 721 89
About this study
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis
The purpose of this study is to evaluate the safety and efficacy of upadacitinib in participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance to or a contraindication for NSAIDs, and who are naïve to biologic disease-modifying anti-rheumatic drugs (bDMARD).
Read the detailed description
This study includes two periods: a 14-week double-blind placebo-controlled period and a 90-week open-label long-term extension period.
Eligible participants were randomly assigned in a 1:1 ratio to receive upadacitinib 15 mg or placebo for 14 weeks in Period 1.
Participants who completed Period 1 received upadacitinib 15 mg for 90 weeks in the extension period.
- Conditions
- Ankylosing Spondylitis (AS)
- Being tested
- Upadacitinib, Placebo
- Keywords
- Upadacitinib, ABT-494, Ankylosing Spondylitis (AS), Safety, Efficacy
- Medical subject headings
- Spondylitis, Ankylosing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
UpadacitinibDrug
Also called ABT-494, RINVOQ™
Tablet
PlaceboDrug
Tablet
| Study group | Role | What they receive |
|---|---|---|
| Upadacitinib 15 mg | Experimental | Participants will receive 15 mg upadacitinib orally once a day for 14 weeks in Period 1 and continue to receive 15 mg upadacitinib orally once a day for an additional 90 weeks in Period 2. Receives: Drug: Upadacitinib |
| Placebo | Placebo comparator | Participants will receive matching placebo orally once a day for 14 weeks in Period 1. In Period 2 participants will receive 15 mg upadacitinib orally once a day for 90 weeks. Receives: Drug: Upadacitinib; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 14
ASAS 40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of > 0 units) in the potential remaining domain:
- Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity);
- Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
- Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
- Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Measured: Baseline and Week 14
Secondary outcomes (12)
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 14
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula:
- Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 [none] - 10 [very severe])
- Patient global assessment of disease activity (NRS score 0 [no activity] - 10 [severe activity])
- Peripheral pain/swelling (BASDAI Question 3; NRS score 0 [none] - 10 [very severe])
- Duration of morning stiffness (BASDAI Question 6; NRS score 0 [0 hours] - 10 [2 or more hours])
- High-sensitivity C-reactive protein (hs-CRP) in mg/L.
The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS < 1.3) and very high disease (ASDAS > 3.5). A negative change from Baseline score indicates improvement in disease activity.
Measured: Baseline and Week 14
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Score for the Spine at Week 14
In the SPARCC MRI assessment of the spine, the entire spine is evaluated for active inflammation (bone marrow edema). Six discovertebral units (DVU) representing the 6 most abnormal DVUs were selected to calculate the MRI Spine SPARCC score. For each of the 6 DVUs, 3 consecutive sagittal slices were assessed in 4 quadrants to evaluate the extent of inflammation in all three dimensions.
Each quadrant was scored for the presence (1) or absence (0) of edema. If edema was present in at least one quadrant of a DVU slice, it was also scored for intensity and depth of the edema representing that slice: An additional score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. Slices that included a lesion demonstrating continuous increased signal of depth ≥ 1 cm extending from the endplate were scored as an additional 1 per slice.
The maximum (worst) overall score for all 6 DVUs is 108.
Measured: Baseline and Week 14
Percentage of Participants With Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response at Week 14
The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale [NRS]) pertaining to symptoms experienced for the past week. For Questions 1 to 5 (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity.
A BASDAI 50 response is defined as improvement of 50% or more from Baseline in BASDAI score.
Measured: Baseline and Week 14
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score
The ASQoL consists of 18 items related to quality of life, including the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. Each item is answered as yes (scored as 1) or no (scored as 0).
Scores are summed to obtain the overall score which ranges from 0 to 18, where higher scores indicate a worse quality of life. A negative change from Baseline in ASQoL indicates improvement in quality of life.
Measured: Baseline and Week 14
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) Partial Remission
ASAS partial remission (PR) is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains:
- Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity);
- Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
- Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
- Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Measured: Week 14
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 14
The Bath Ankylosing Spondylitis Functional Index is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities such as putting on socks, bending, reaching, getting up from the floor or an armless chair, standing, climbing and other physical activities. Each item is scored on a NRS ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher scores indicating more functional limitations. A negative change from Baseline in BASFI indicates improvement.
Measured: Baseline and Week 14
Change From Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMI[Lin]) at Week 14
The BASMI is a composite score based on 5 direct measurements of spinal mobility:
- cervical rotation (measured in degrees),
- tragus to wall distance (in centimeters [cm])
- lumbar side flexion (in cm),
- lumbar flexion (modified Schober's) (in cm) and
- intermalleolar distance (in cm).
Each measurement is converted to a linear score between 0 and 10. The total BASMI score is the average of the 5 scores and ranges from 0 to 10; the higher the BASMI score the more severe the patient's limitation of movement due to their ankylosing spondylitis. A negative change from Baseline indicates improvement.
Measured: Baseline and Week 14
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 14
The MASES evaluation was conducted to assess the presence or absence of enthesitis (inflammation of the entheses, or sites where tendons or ligaments insert into the bone) at 13 different sites (first costochondral joint left/right, seventh costochondral joint left/right, posterior superior iliac spine left/right, anterior superior iliac spine left/right, iliac crest left/right, fifth lumbar spinous process, and proximal insertion of Achilles tendon left/right. Each site was scored for presence (1) or absence (0) of enthesitis. The MASES is the sum of the 13 site scores, and ranges from 0 to 13, with higher scores indicating more inflammation of the entheses.
Measured: Baseline and Week 14
Change From Baseline in Work Productivity and Activity Impairment (WPAI) Overall Work Impairment at Week 14
The Work Productivity and Activity Impairment Questionnaire: Axial Spondyloarthritis, Version 2.0 (WPAI-Axial Spondyloarthritis) measures the effect of overall health and specific symptoms on productivity at work and outside of work. It consists of 6 questions. Respondents were asked about time missed from work and time while at work during which productivity was impaired in the past seven days. Results of WPAI are expressed as a percentage of impairment from 0 to 100, with higher percentages indicating greater impairment and less productivity. Overall Work Impairment indicates the percentage of overall work impairment due to health problems. A negative change from Baseline indicates improvement.
Measured: Baseline and Week 14
Change From Baseline in ASAS Health Index (HI) at Week 14
The ASAS HI measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. Each of the 17 questions is answered by the participant as "I agree" (score = 1) or "I disagree" (score = 0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, where a higher score indicates a worse health status. A negative change from Baseline indicates improvement.
Measured: Baseline and Week 14
Percentage of Participants Achieving an ASAS 20 Response at Week 14
ASAS 20 response was defined as an improvement of ≥ 20% and an absolute improvement of ≥ 1 unit (on a scale of 0 to 10) from Baseline in at least 3 of the following 4 domains, with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 units [on a scale of 0 to 10]) in the remaining domain:
- Patient's global assessment of disease activity, measured on a NRS from 0 (no activity) to 10 (severe activity);
- Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain);
- Function, measured by the BASFI which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible);
- Inflammation, measured by the mean of the 2 morning stiffness-related BASDAI NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Measured: Baseline and Week 14
Change From Baseline in SPARCC MRI Score for Sacroiliac Joints at Week 14
In the SPARCC MRI assessment of the sacroiliac (SI) joints 6 consecutive sacroiliac joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema.
Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema, intensity of edema (a score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice), and a lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant.
The total maximum score for all SI joints across 6 slices is 72.
Measured: Baseline and Week 14
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jun 2017
- Study start24 Oct 2017
- Primary completion21 Jan 2019
- Study completion17 Feb 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (11)Papers the sponsor has linked to this study.
- Other trials for Ankylosing Spondylitis (AS)Studies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 187 participants (actual)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- AbbVie Inc., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03178487
- Sponsor's protocol ID
- M16-098
- Other IDs
- 2017-000431-14, 2017
- Acronym
- SELECT-AXIS 1
- Status last verified
- Feb 2023
- First submitted
- 5 Jun 2017
- Last updated
- 7 Mar 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Publications
van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Everding A, Sui Y, Wang X, Chu AD, Sieper J. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019 Dec 7;394(10214):2108-2117. doi: 10.1016/S0140-6736(19)32534-6. Epub 2019 Nov 12.
PubMed 31732180Baraliakos X, Bessette L, de Vlam K, Taylor PC, Biljan A, Urbanik J, Gao T, Jasion VS, Kato K, Lippe R, Magrey M. Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS Studies. Rheumatol Ther. 2026 Jun;13(3):611-628. doi: 10.1007/s40744-026-00834-5. Epub 2026 Mar 13.
PubMed 41824252Zhang X, Jia L, Lin X, Zhou L. Exhaustion-Resistant CD8 + T Cells in Ankylosing Spondylitis: A Proposed Three-Axis Model. Immunology. 2025 Dec;176(4):409-420. doi: 10.1111/imm.70044. Epub 2025 Oct 2.
PubMed 41039829Burmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, Levy G, Suravaram S, Palac H, Wegrzyn L, Ford S, Meerwein S, Guttman-Yassky E. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. Adv Ther. 2025 Oct;42(10):5215-5237. doi: 10.1007/s12325-025-03328-y. Epub 2025 Aug 28.
PubMed 40875187Navarro-Compan V, Van den Bosch F, Sampaio-Barros PD, Ostor AJK, Parikh B, Kato K, Gao T, Stigler J, Ramiro S. Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease. RMD Open. 2025 Mar 4;11(1):e005110. doi: 10.1136/rmdopen-2024-005110.
PubMed 40037923Poddubnyy D, Parikh B, Elewaut D, Navarro-Compan V, Siebert S, Paley M, Coombs D, Lagunes I, Biljan A, Nakasato P, Wung P, Lubrano E. Development of Extramusculoskeletal Manifestations in Upadacitinib-Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis. Arthritis Rheumatol. 2025 May;77(5):536-546. doi: 10.1002/art.43069. Epub 2025 Jan 24.
PubMed 39624020Burmester GR, Stigler J, Rubbert-Roth A, Tanaka Y, Azevedo VF, Coombs D, Lagunes I, Lippe R, Wung P, Gensler LS. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Rheumatol Ther. 2024 Jun;11(3):737-753. doi: 10.1007/s40744-024-00671-4. Epub 2024 Apr 29.
PubMed 38683479Rubbert-Roth A, Kakehasi AM, Takeuchi T, Schmalzing M, Palac H, Coombs D, Liu J, Anyanwu SI, Lippe R, Curtis JR. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis. Rheumatol Ther. 2024 Feb;11(1):97-112. doi: 10.1007/s40744-023-00621-6. Epub 2023 Nov 20.
PubMed 37982966Charles-Schoeman C, Choy E, McInnes IB, Mysler E, Nash P, Yamaoka K, Lippe R, Khan N, Shmagel AK, Palac H, Suboticki J, Curtis JR. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023 Nov;9(4):e003392. doi: 10.1136/rmdopen-2023-003392.
PubMed 37945286Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023 Feb;9(1):e002735. doi: 10.1136/rmdopen-2022-002735.
PubMed 36754548Deodhar A, van der Heijde D, Sieper J, Van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Ostor A, Combe B, Sui Y, Chu AD, Song IH. Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension. Arthritis Rheumatol. 2022 Jan;74(1):70-80. doi: 10.1002/art.41911. Epub 2021 Nov 12.
PubMed 34196498
Study at a glance
From the registry record, last updated by the sponsor on 7 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis
- ClinicalTrials.gov ID
- NCT03178487
- Acronym / sponsor ID
- SELECT-AXIS 1 / M16-098
- Conditions
- Ankylosing Spondylitis (AS)
- Keywords
- Upadacitinib, ABT-494, Ankylosing Spondylitis (AS), Safety, Efficacy
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 187 participants (actual)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 24 Oct 2017 (actual)
- Primary completion
- 21 Jan 2019 (actual)
- Study completion
- 17 Feb 2022 (actual)
- First posted
- 7 Jun 2017 (actual)
- Results
- Posted 1 Jun 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate the safety and efficacy of upadacitinib in participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance to or a contraindication for NSAIDs, and who are naïve to biologic disease-modifying anti-rheumatic drugs (bDMARD).
Detailed description
This study includes two periods: a 14-week double-blind placebo-controlled period and a 90-week open-label long-term extension period.
Eligible participants were randomly assigned in a 1:1 ratio to receive upadacitinib 15 mg or placebo for 14 weeks in Period 1.
Participants who completed Period 1 received upadacitinib 15 mg for 90 weeks in the extension period.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Upadacitinib 15 mg | Experimental | Drug: UpadacitinibParticipants will receive 15 mg upadacitinib orally once a day for 14 weeks in Period 1 and continue to receive 15 mg upadacitinib orally once a day for an additional 90 weeks in Period 2. |
| Placebo | Placebo comparator | Drug: Upadacitinib, Drug: PlaceboParticipants will receive matching placebo orally once a day for 14 weeks in Period 1. In Period 2 participants will receive 15 mg upadacitinib orally once a day for 90 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Participant with a clinical diagnosis of ankylosing spondylitis (AS) and meeting the modified New York criteria for AS.
- Participant must have baseline disease activity as defined by having a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score >= 4 and a Patient's Assessment of Total Back Pain score >= 4 based on a 0 - 10 numeric rating scale (NRS) at the Screening and Baseline visits.
- Participant has had an inadequate response to at least two nonsteroidal anti-inflammatory drugs (NSAIDs) over an at least 4-week period in total at maximum recommended or tolerated doses, or participant has an intolerance to or contraindication for NSAIDs as defined by the Investigator.
- If entering the study on concomitant methotrexate (MTX), leflunomide, sulfasalazine (SSZ), and/or hydroxychloroquine, participant must be on a stable dose of MTX (<= 25 mg/week) and/or SSZ (<= 3 g/day) and/or hydroxychloroquine (<= 400 mg/day) or leflunomide (<= 20 mg/day) for at least 28 days prior to the Baseline visit. A combination of up to two background conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) is allowed except the combination of MTX and leflunomide.
- If entering the study on concomitant oral corticosteroids, participant must be on a stable dose of prednisone (<= 10 mg/day), or oral corticosteroid equivalents, for at least 14 days prior to the Baseline visit.
Key exclusion criteria (7 listed)
- Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib).
- Prior exposure to any biologic therapy with a potential therapeutic impact on spondyloarthritis (SpA).
- Intra-articular joint injections, spinal/paraspinal injection(s), or parenteral administration of corticosteroids within 28 days prior to the Baseline visit. Inhaled or topical corticosteroids are allowed.
- Participant on any other DMARDs (other than those allowed), thalidomide or apremilast within 28 days or five half-lives (whichever is longer) of the drug prior to the Baseline visit.
- Participant on opioid analgesics (except for combination acetaminophen/codeine or acetaminophen/hydrocodone which are allowed) or use of inhaled marijuana within 14 days prior to the Baseline visit.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| UpadacitinibAlso: ABT-494, RINVOQ™Tablet | Drug | Placebo, Upadacitinib 15 mg |
| PlaceboTablet | Drug | Placebo |
Primary outcome
Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 14
Time frame: Baseline and Week 14
ASAS 40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of > 0 units) in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 [level of stiffness] and 6 [duration of stiffness]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
12 secondary outcomes
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 14
Time frame: Baseline and Week 14
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Score for the Spine at Week 14
Time frame: Baseline and Week 14
Percentage of Participants With Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response at Week 14
Time frame: Baseline and Week 14
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score
Time frame: Baseline and Week 14
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) Partial Remission
Time frame: Week 14
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 14
Time frame: Baseline and Week 14
Change From Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMI[Lin]) at Week 14
Time frame: Baseline and Week 14
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 14
Time frame: Baseline and Week 14
Change From Baseline in Work Productivity and Activity Impairment (WPAI) Overall Work Impairment at Week 14
Time frame: Baseline and Week 14
Change From Baseline in ASAS Health Index (HI) at Week 14
Time frame: Baseline and Week 14
Percentage of Participants Achieving an ASAS 20 Response at Week 14
Time frame: Baseline and Week 14
Change From Baseline in SPARCC MRI Score for Sacroiliac Joints at Week 14
Time frame: Baseline and Week 14
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Mar 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 31732180van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Everding A, Sui Y, Wang X, Chu AD, Sieper J. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019 Dec 7;394(10214):2108-2117. doi: 10.1016/S0140-6736(19)32534-6. Epub 2019 Nov 12.
- Derived from this study: PubMed 41824252Baraliakos X, Bessette L, de Vlam K, Taylor PC, Biljan A, Urbanik J, Gao T, Jasion VS, Kato K, Lippe R, Magrey M. Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS Studies. Rheumatol Ther. 2026 Jun;13(3):611-628. doi: 10.1007/s40744-026-00834-5. Epub 2026 Mar 13.
- Derived from this study: PubMed 41039829Zhang X, Jia L, Lin X, Zhou L. Exhaustion-Resistant CD8 + T Cells in Ankylosing Spondylitis: A Proposed Three-Axis Model. Immunology. 2025 Dec;176(4):409-420. doi: 10.1111/imm.70044. Epub 2025 Oct 2.
- Derived from this study: PubMed 40875187Burmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, Levy G, Suravaram S, Palac H, Wegrzyn L, Ford S, Meerwein S, Guttman-Yassky E. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. Adv Ther. 2025 Oct;42(10):5215-5237. doi: 10.1007/s12325-025-03328-y. Epub 2025 Aug 28.
- Derived from this study: PubMed 40037923Navarro-Compan V, Van den Bosch F, Sampaio-Barros PD, Ostor AJK, Parikh B, Kato K, Gao T, Stigler J, Ramiro S. Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease. RMD Open. 2025 Mar 4;11(1):e005110. doi: 10.1136/rmdopen-2024-005110.
- Derived from this study: PubMed 39624020Poddubnyy D, Parikh B, Elewaut D, Navarro-Compan V, Siebert S, Paley M, Coombs D, Lagunes I, Biljan A, Nakasato P, Wung P, Lubrano E. Development of Extramusculoskeletal Manifestations in Upadacitinib-Treated Patients With Psoriatic Arthritis or Axial Spondyloarthritis. Arthritis Rheumatol. 2025 May;77(5):536-546. doi: 10.1002/art.43069. Epub 2025 Jan 24.
- Derived from this study: PubMed 38683479Burmester GR, Stigler J, Rubbert-Roth A, Tanaka Y, Azevedo VF, Coombs D, Lagunes I, Lippe R, Wung P, Gensler LS. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials. Rheumatol Ther. 2024 Jun;11(3):737-753. doi: 10.1007/s40744-024-00671-4. Epub 2024 Apr 29.
- Derived from this study: PubMed 37982966Rubbert-Roth A, Kakehasi AM, Takeuchi T, Schmalzing M, Palac H, Coombs D, Liu J, Anyanwu SI, Lippe R, Curtis JR. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis. Rheumatol Ther. 2024 Feb;11(1):97-112. doi: 10.1007/s40744-023-00621-6. Epub 2023 Nov 20.
- Derived from this study: PubMed 37945286Charles-Schoeman C, Choy E, McInnes IB, Mysler E, Nash P, Yamaoka K, Lippe R, Khan N, Shmagel AK, Palac H, Suboticki J, Curtis JR. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023 Nov;9(4):e003392. doi: 10.1136/rmdopen-2023-003392.
- Derived from this study: PubMed 36754548Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023 Feb;9(1):e002735. doi: 10.1136/rmdopen-2022-002735.
- Derived from this study: PubMed 34196498Deodhar A, van der Heijde D, Sieper J, Van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Ostor A, Combe B, Sui Y, Chu AD, Song IH. Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension. Arthritis Rheumatol. 2022 Jan;74(1):70-80. doi: 10.1002/art.41911. Epub 2021 Nov 12.
- Individual participant dataSharing planned: Yes. AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Related trials for Ankylosing Spondylitis (AS)
RecruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
Active, not recruitingObservational study
Neuropathic Spinal Pain in Ankylosing Spondylitis
Ankylosing Spondylitis
Not yet recruitingPhase 1
A Study of GKL-006Allo Injection in Patients With Ankylosing Spondylitis
Ankylosing Spondylitis
RecruitingPhase 1
Phase Ia Study of MST-931 in Healthy Adult Subjects
Ankylosing Spondylitis (AS)
Not yet recruitingObservational study
SLAMF1 Gene Expression in Ankylosing Spondylitis
Ankylosing Spondylitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
AbbVie Inc. study director
AbbVie
101 sites in 21 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Upadacitinib in people with Ankylosing Spondylitis (AS), run by AbbVie at 101 sites in 21 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 101 sites in United States, Japan, South Korea, Portugal, United Kingdom and 16 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 1 Jun 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 14 (time frame: Baseline and Week 14). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03178487, which also lists 11 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2023; AzTrials last refreshed its copy on 6 Nov 2026.